Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Fineline Cube Feb 24, 2025

Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...

Company Deals Drug

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Fineline Cube Feb 24, 2025

Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...

Company Deals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

Fineline Cube Feb 24, 2025

Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...

Company Drug

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment

Fineline Cube Feb 24, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...

Company Medical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

Fineline Cube Feb 24, 2025

Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...

Company Deals

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech

Fineline Cube Feb 24, 2025

Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...

Company Deals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines

Fineline Cube Feb 24, 2025

China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...

Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Company Drug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Fineline Cube Feb 24, 2025

China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...

Company Drug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Fineline Cube Feb 24, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...

Company Drug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Fineline Cube Feb 24, 2025

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...

Company Deals

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights

Fineline Cube Feb 24, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...

Company Drug

Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer

Fineline Cube Feb 24, 2025

Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....

Company Drug

Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress

Fineline Cube Feb 24, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...

Company Drug

Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy

Fineline Cube Feb 24, 2025

China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...

Company Drug

J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction

Fineline Cube Feb 24, 2025

U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...

Company Medical Device

MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval

Fineline Cube Feb 24, 2025

Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for...

Company Drug

AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design

Fineline Cube Feb 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...

Posts pagination

1 … 203 204 205 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.